Global Lunasin

Lunasin Comprehensive Study by Type (Capsule, Powder, Others), Application (Healthcare Supplements, Medical Treatments, Other), Administration (Oral, Injectable) Players and Region - Global Market Outlook to 2030

Lunasin Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lunasin
Lunasin, a bioactive peptide produced from soy, is one of the most promising. Lunasin, a peptide isolated from soybean seed, is encoded by the 2S albumin (GM2S-1) gene. It has a molecular weight of 5.5 kDa and is made up of 43 amino acid residues. Lunasin appears to stop cancer cells from mutating into normal ones. Lunasin appears to accomplish this by preventing a number of important events that occur when normal cells are exposed to cancer-causing substances known as carcinogens. Lunasin may also help to lower cholesterol levels in the body.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focused on production technologies, efficiency enhancement, and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge investments in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lunasin market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Reliv International Inc. (United States), PatientsLikeMe (England), Carefast (United States), Simplesa Nutrition Corp (United States), Luna-Code (United States), Soy LabsLLC (United States), Scientific health solutions (United States) and Collagen (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Lunasin market by Type (Capsule, Powder and Others), Application (Healthcare Supplements, Medical Treatments and Other) and Region.



On the basis of geography, the market of Lunasin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Administration, the sub-segment i.e. Oral will boost the Lunasin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Development of Lunasin based health-promoting products or drugs

Market Growth Drivers:
Increasing prevalence of cancer and Rising adoption due to its high benefits such as playing a vital role in regulating cholesterol biosynthesis in the body

Challenges:
Lack of effective techniques for obtaining a significant amount of pure Lunasin

Restraints:
Commercial price is quite high due to its costly and time-consuming synthesis process

Opportunities:
Rising adoption of Lunasin to prevention and treatment of cancer and Rising Healthcare Expenditure

Market Leaders and their expansionary development strategies
In July 2023, Eli Lilly and Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
In December 2020- Reliv International, a developer, and marketer of nutritional supplements that promote optimal nutrition and specialized solutions of LunaRich products which are made up of the Lunasin.


Key Target Audience
Manufacturers, Distributors and Suppliers, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Capsule
  • Powder
  • Others
By Application
  • Healthcare Supplements
  • Medical Treatments
  • Other
By Administration
  • Oral
  • Injectable

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of cancer
      • 3.2.2. Rising adoption due to its high benefits such as playing a vital role in regulating cholesterol biosynthesis in the body
    • 3.3. Market Challenges
      • 3.3.1. Lack of effective techniques for obtaining a significant amount of pure Lunasin
    • 3.4. Market Trends
      • 3.4.1. Development of Lunasin based health-promoting products or drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lunasin, by Type, Application, Administration and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lunasin (Value)
      • 5.2.1. Global Lunasin by: Type (Value)
        • 5.2.1.1. Capsule
        • 5.2.1.2. Powder
        • 5.2.1.3. Others
      • 5.2.2. Global Lunasin by: Application (Value)
        • 5.2.2.1. Healthcare Supplements
        • 5.2.2.2. Medical Treatments
        • 5.2.2.3. Other
      • 5.2.3. Global Lunasin by: Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectable
      • 5.2.4. Global Lunasin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Lunasin (Price)
      • 5.3.1. Global Lunasin by: Type (Price)
  • 6. Lunasin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Reliv International Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PatientsLikeMe (England)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Carefast (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Simplesa Nutrition Corp (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Luna-Code (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Soy LabsLLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Scientific health solutions (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Collagen (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Lunasin Sale, by Type, Application, Administration and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lunasin (Value)
      • 7.2.1. Global Lunasin by: Type (Value)
        • 7.2.1.1. Capsule
        • 7.2.1.2. Powder
        • 7.2.1.3. Others
      • 7.2.2. Global Lunasin by: Application (Value)
        • 7.2.2.1. Healthcare Supplements
        • 7.2.2.2. Medical Treatments
        • 7.2.2.3. Other
      • 7.2.3. Global Lunasin by: Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectable
      • 7.2.4. Global Lunasin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Lunasin (Price)
      • 7.3.1. Global Lunasin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lunasin: by Type(USD Million)
  • Table 2. Lunasin Capsule , by Region USD Million (2018-2023)
  • Table 3. Lunasin Powder , by Region USD Million (2018-2023)
  • Table 4. Lunasin Others , by Region USD Million (2018-2023)
  • Table 5. Lunasin: by Application(USD Million)
  • Table 6. Lunasin Healthcare Supplements , by Region USD Million (2018-2023)
  • Table 7. Lunasin Medical Treatments , by Region USD Million (2018-2023)
  • Table 8. Lunasin Other , by Region USD Million (2018-2023)
  • Table 9. Lunasin: by Administration(USD Million)
  • Table 10. Lunasin Oral , by Region USD Million (2018-2023)
  • Table 11. Lunasin Injectable , by Region USD Million (2018-2023)
  • Table 12. South America Lunasin, by Country USD Million (2018-2023)
  • Table 13. South America Lunasin, by Type USD Million (2018-2023)
  • Table 14. South America Lunasin, by Application USD Million (2018-2023)
  • Table 15. South America Lunasin, by Administration USD Million (2018-2023)
  • Table 16. Brazil Lunasin, by Type USD Million (2018-2023)
  • Table 17. Brazil Lunasin, by Application USD Million (2018-2023)
  • Table 18. Brazil Lunasin, by Administration USD Million (2018-2023)
  • Table 19. Argentina Lunasin, by Type USD Million (2018-2023)
  • Table 20. Argentina Lunasin, by Application USD Million (2018-2023)
  • Table 21. Argentina Lunasin, by Administration USD Million (2018-2023)
  • Table 22. Rest of South America Lunasin, by Type USD Million (2018-2023)
  • Table 23. Rest of South America Lunasin, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Lunasin, by Administration USD Million (2018-2023)
  • Table 25. Asia Pacific Lunasin, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Lunasin, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Lunasin, by Application USD Million (2018-2023)
  • Table 28. Asia Pacific Lunasin, by Administration USD Million (2018-2023)
  • Table 29. China Lunasin, by Type USD Million (2018-2023)
  • Table 30. China Lunasin, by Application USD Million (2018-2023)
  • Table 31. China Lunasin, by Administration USD Million (2018-2023)
  • Table 32. Japan Lunasin, by Type USD Million (2018-2023)
  • Table 33. Japan Lunasin, by Application USD Million (2018-2023)
  • Table 34. Japan Lunasin, by Administration USD Million (2018-2023)
  • Table 35. India Lunasin, by Type USD Million (2018-2023)
  • Table 36. India Lunasin, by Application USD Million (2018-2023)
  • Table 37. India Lunasin, by Administration USD Million (2018-2023)
  • Table 38. South Korea Lunasin, by Type USD Million (2018-2023)
  • Table 39. South Korea Lunasin, by Application USD Million (2018-2023)
  • Table 40. South Korea Lunasin, by Administration USD Million (2018-2023)
  • Table 41. Taiwan Lunasin, by Type USD Million (2018-2023)
  • Table 42. Taiwan Lunasin, by Application USD Million (2018-2023)
  • Table 43. Taiwan Lunasin, by Administration USD Million (2018-2023)
  • Table 44. Australia Lunasin, by Type USD Million (2018-2023)
  • Table 45. Australia Lunasin, by Application USD Million (2018-2023)
  • Table 46. Australia Lunasin, by Administration USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Lunasin, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Lunasin, by Application USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Lunasin, by Administration USD Million (2018-2023)
  • Table 50. Europe Lunasin, by Country USD Million (2018-2023)
  • Table 51. Europe Lunasin, by Type USD Million (2018-2023)
  • Table 52. Europe Lunasin, by Application USD Million (2018-2023)
  • Table 53. Europe Lunasin, by Administration USD Million (2018-2023)
  • Table 54. Germany Lunasin, by Type USD Million (2018-2023)
  • Table 55. Germany Lunasin, by Application USD Million (2018-2023)
  • Table 56. Germany Lunasin, by Administration USD Million (2018-2023)
  • Table 57. France Lunasin, by Type USD Million (2018-2023)
  • Table 58. France Lunasin, by Application USD Million (2018-2023)
  • Table 59. France Lunasin, by Administration USD Million (2018-2023)
  • Table 60. Italy Lunasin, by Type USD Million (2018-2023)
  • Table 61. Italy Lunasin, by Application USD Million (2018-2023)
  • Table 62. Italy Lunasin, by Administration USD Million (2018-2023)
  • Table 63. United Kingdom Lunasin, by Type USD Million (2018-2023)
  • Table 64. United Kingdom Lunasin, by Application USD Million (2018-2023)
  • Table 65. United Kingdom Lunasin, by Administration USD Million (2018-2023)
  • Table 66. Netherlands Lunasin, by Type USD Million (2018-2023)
  • Table 67. Netherlands Lunasin, by Application USD Million (2018-2023)
  • Table 68. Netherlands Lunasin, by Administration USD Million (2018-2023)
  • Table 69. Rest of Europe Lunasin, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe Lunasin, by Application USD Million (2018-2023)
  • Table 71. Rest of Europe Lunasin, by Administration USD Million (2018-2023)
  • Table 72. MEA Lunasin, by Country USD Million (2018-2023)
  • Table 73. MEA Lunasin, by Type USD Million (2018-2023)
  • Table 74. MEA Lunasin, by Application USD Million (2018-2023)
  • Table 75. MEA Lunasin, by Administration USD Million (2018-2023)
  • Table 76. Middle East Lunasin, by Type USD Million (2018-2023)
  • Table 77. Middle East Lunasin, by Application USD Million (2018-2023)
  • Table 78. Middle East Lunasin, by Administration USD Million (2018-2023)
  • Table 79. Africa Lunasin, by Type USD Million (2018-2023)
  • Table 80. Africa Lunasin, by Application USD Million (2018-2023)
  • Table 81. Africa Lunasin, by Administration USD Million (2018-2023)
  • Table 82. North America Lunasin, by Country USD Million (2018-2023)
  • Table 83. North America Lunasin, by Type USD Million (2018-2023)
  • Table 84. North America Lunasin, by Application USD Million (2018-2023)
  • Table 85. North America Lunasin, by Administration USD Million (2018-2023)
  • Table 86. United States Lunasin, by Type USD Million (2018-2023)
  • Table 87. United States Lunasin, by Application USD Million (2018-2023)
  • Table 88. United States Lunasin, by Administration USD Million (2018-2023)
  • Table 89. Canada Lunasin, by Type USD Million (2018-2023)
  • Table 90. Canada Lunasin, by Application USD Million (2018-2023)
  • Table 91. Canada Lunasin, by Administration USD Million (2018-2023)
  • Table 92. Mexico Lunasin, by Type USD Million (2018-2023)
  • Table 93. Mexico Lunasin, by Application USD Million (2018-2023)
  • Table 94. Mexico Lunasin, by Administration USD Million (2018-2023)
  • Table 95. Lunasin: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Lunasin: by Type(USD Million)
  • Table 105. Lunasin Capsule , by Region USD Million (2025-2030)
  • Table 106. Lunasin Powder , by Region USD Million (2025-2030)
  • Table 107. Lunasin Others , by Region USD Million (2025-2030)
  • Table 108. Lunasin: by Application(USD Million)
  • Table 109. Lunasin Healthcare Supplements , by Region USD Million (2025-2030)
  • Table 110. Lunasin Medical Treatments , by Region USD Million (2025-2030)
  • Table 111. Lunasin Other , by Region USD Million (2025-2030)
  • Table 112. Lunasin: by Administration(USD Million)
  • Table 113. Lunasin Oral , by Region USD Million (2025-2030)
  • Table 114. Lunasin Injectable , by Region USD Million (2025-2030)
  • Table 115. South America Lunasin, by Country USD Million (2025-2030)
  • Table 116. South America Lunasin, by Type USD Million (2025-2030)
  • Table 117. South America Lunasin, by Application USD Million (2025-2030)
  • Table 118. South America Lunasin, by Administration USD Million (2025-2030)
  • Table 119. Brazil Lunasin, by Type USD Million (2025-2030)
  • Table 120. Brazil Lunasin, by Application USD Million (2025-2030)
  • Table 121. Brazil Lunasin, by Administration USD Million (2025-2030)
  • Table 122. Argentina Lunasin, by Type USD Million (2025-2030)
  • Table 123. Argentina Lunasin, by Application USD Million (2025-2030)
  • Table 124. Argentina Lunasin, by Administration USD Million (2025-2030)
  • Table 125. Rest of South America Lunasin, by Type USD Million (2025-2030)
  • Table 126. Rest of South America Lunasin, by Application USD Million (2025-2030)
  • Table 127. Rest of South America Lunasin, by Administration USD Million (2025-2030)
  • Table 128. Asia Pacific Lunasin, by Country USD Million (2025-2030)
  • Table 129. Asia Pacific Lunasin, by Type USD Million (2025-2030)
  • Table 130. Asia Pacific Lunasin, by Application USD Million (2025-2030)
  • Table 131. Asia Pacific Lunasin, by Administration USD Million (2025-2030)
  • Table 132. China Lunasin, by Type USD Million (2025-2030)
  • Table 133. China Lunasin, by Application USD Million (2025-2030)
  • Table 134. China Lunasin, by Administration USD Million (2025-2030)
  • Table 135. Japan Lunasin, by Type USD Million (2025-2030)
  • Table 136. Japan Lunasin, by Application USD Million (2025-2030)
  • Table 137. Japan Lunasin, by Administration USD Million (2025-2030)
  • Table 138. India Lunasin, by Type USD Million (2025-2030)
  • Table 139. India Lunasin, by Application USD Million (2025-2030)
  • Table 140. India Lunasin, by Administration USD Million (2025-2030)
  • Table 141. South Korea Lunasin, by Type USD Million (2025-2030)
  • Table 142. South Korea Lunasin, by Application USD Million (2025-2030)
  • Table 143. South Korea Lunasin, by Administration USD Million (2025-2030)
  • Table 144. Taiwan Lunasin, by Type USD Million (2025-2030)
  • Table 145. Taiwan Lunasin, by Application USD Million (2025-2030)
  • Table 146. Taiwan Lunasin, by Administration USD Million (2025-2030)
  • Table 147. Australia Lunasin, by Type USD Million (2025-2030)
  • Table 148. Australia Lunasin, by Application USD Million (2025-2030)
  • Table 149. Australia Lunasin, by Administration USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Lunasin, by Type USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Lunasin, by Application USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Lunasin, by Administration USD Million (2025-2030)
  • Table 153. Europe Lunasin, by Country USD Million (2025-2030)
  • Table 154. Europe Lunasin, by Type USD Million (2025-2030)
  • Table 155. Europe Lunasin, by Application USD Million (2025-2030)
  • Table 156. Europe Lunasin, by Administration USD Million (2025-2030)
  • Table 157. Germany Lunasin, by Type USD Million (2025-2030)
  • Table 158. Germany Lunasin, by Application USD Million (2025-2030)
  • Table 159. Germany Lunasin, by Administration USD Million (2025-2030)
  • Table 160. France Lunasin, by Type USD Million (2025-2030)
  • Table 161. France Lunasin, by Application USD Million (2025-2030)
  • Table 162. France Lunasin, by Administration USD Million (2025-2030)
  • Table 163. Italy Lunasin, by Type USD Million (2025-2030)
  • Table 164. Italy Lunasin, by Application USD Million (2025-2030)
  • Table 165. Italy Lunasin, by Administration USD Million (2025-2030)
  • Table 166. United Kingdom Lunasin, by Type USD Million (2025-2030)
  • Table 167. United Kingdom Lunasin, by Application USD Million (2025-2030)
  • Table 168. United Kingdom Lunasin, by Administration USD Million (2025-2030)
  • Table 169. Netherlands Lunasin, by Type USD Million (2025-2030)
  • Table 170. Netherlands Lunasin, by Application USD Million (2025-2030)
  • Table 171. Netherlands Lunasin, by Administration USD Million (2025-2030)
  • Table 172. Rest of Europe Lunasin, by Type USD Million (2025-2030)
  • Table 173. Rest of Europe Lunasin, by Application USD Million (2025-2030)
  • Table 174. Rest of Europe Lunasin, by Administration USD Million (2025-2030)
  • Table 175. MEA Lunasin, by Country USD Million (2025-2030)
  • Table 176. MEA Lunasin, by Type USD Million (2025-2030)
  • Table 177. MEA Lunasin, by Application USD Million (2025-2030)
  • Table 178. MEA Lunasin, by Administration USD Million (2025-2030)
  • Table 179. Middle East Lunasin, by Type USD Million (2025-2030)
  • Table 180. Middle East Lunasin, by Application USD Million (2025-2030)
  • Table 181. Middle East Lunasin, by Administration USD Million (2025-2030)
  • Table 182. Africa Lunasin, by Type USD Million (2025-2030)
  • Table 183. Africa Lunasin, by Application USD Million (2025-2030)
  • Table 184. Africa Lunasin, by Administration USD Million (2025-2030)
  • Table 185. North America Lunasin, by Country USD Million (2025-2030)
  • Table 186. North America Lunasin, by Type USD Million (2025-2030)
  • Table 187. North America Lunasin, by Application USD Million (2025-2030)
  • Table 188. North America Lunasin, by Administration USD Million (2025-2030)
  • Table 189. United States Lunasin, by Type USD Million (2025-2030)
  • Table 190. United States Lunasin, by Application USD Million (2025-2030)
  • Table 191. United States Lunasin, by Administration USD Million (2025-2030)
  • Table 192. Canada Lunasin, by Type USD Million (2025-2030)
  • Table 193. Canada Lunasin, by Application USD Million (2025-2030)
  • Table 194. Canada Lunasin, by Administration USD Million (2025-2030)
  • Table 195. Mexico Lunasin, by Type USD Million (2025-2030)
  • Table 196. Mexico Lunasin, by Application USD Million (2025-2030)
  • Table 197. Mexico Lunasin, by Administration USD Million (2025-2030)
  • Table 198. Lunasin: by Type(USD/Units)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lunasin: by Type USD Million (2018-2023)
  • Figure 5. Global Lunasin: by Application USD Million (2018-2023)
  • Figure 6. Global Lunasin: by Administration USD Million (2018-2023)
  • Figure 7. South America Lunasin Share (%), by Country
  • Figure 8. Asia Pacific Lunasin Share (%), by Country
  • Figure 9. Europe Lunasin Share (%), by Country
  • Figure 10. MEA Lunasin Share (%), by Country
  • Figure 11. North America Lunasin Share (%), by Country
  • Figure 12. Global Lunasin: by Type USD/Units (2018-2023)
  • Figure 13. Global Lunasin share by Players 2023 (%)
  • Figure 14. Global Lunasin share by Players (Top 3) 2023(%)
  • Figure 15. Global Lunasin share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Reliv International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Reliv International Inc. (United States) Revenue: by Geography 2023
  • Figure 19. PatientsLikeMe (England) Revenue, Net Income and Gross profit
  • Figure 20. PatientsLikeMe (England) Revenue: by Geography 2023
  • Figure 21. Carefast (United States) Revenue, Net Income and Gross profit
  • Figure 22. Carefast (United States) Revenue: by Geography 2023
  • Figure 23. Simplesa Nutrition Corp (United States) Revenue, Net Income and Gross profit
  • Figure 24. Simplesa Nutrition Corp (United States) Revenue: by Geography 2023
  • Figure 25. Luna-Code (United States) Revenue, Net Income and Gross profit
  • Figure 26. Luna-Code (United States) Revenue: by Geography 2023
  • Figure 27. Soy LabsLLC (United States) Revenue, Net Income and Gross profit
  • Figure 28. Soy LabsLLC (United States) Revenue: by Geography 2023
  • Figure 29. Scientific health solutions (United States) Revenue, Net Income and Gross profit
  • Figure 30. Scientific health solutions (United States) Revenue: by Geography 2023
  • Figure 31. Collagen (United States) Revenue, Net Income and Gross profit
  • Figure 32. Collagen (United States) Revenue: by Geography 2023
  • Figure 33. Global Lunasin: by Type USD Million (2025-2030)
  • Figure 34. Global Lunasin: by Application USD Million (2025-2030)
  • Figure 35. Global Lunasin: by Administration USD Million (2025-2030)
  • Figure 36. South America Lunasin Share (%), by Country
  • Figure 37. Asia Pacific Lunasin Share (%), by Country
  • Figure 38. Europe Lunasin Share (%), by Country
  • Figure 39. MEA Lunasin Share (%), by Country
  • Figure 40. North America Lunasin Share (%), by Country
  • Figure 41. Global Lunasin: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Reliv International Inc. (United States)
  • PatientsLikeMe (England)
  • Carefast (United States)
  • Simplesa Nutrition Corp (United States)
  • Luna-Code (United States)
  • Soy LabsLLC (United States)
  • Scientific health solutions (United States)
  • Collagen (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 235 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lunasin Quantitative research analysis
Global Lunasin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Reliv International Inc. (United States), PatientsLikeMe (England), Carefast (United States), Simplesa Nutrition Corp (United States), Luna-Code (United States), Soy LabsLLC (United States), Scientific health solutions (United States) and Collagen (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Development of Lunasin based health-promoting products or drugs" is seen as one of major influencing trends for Lunasin Market during projected period 2023-2030.
The Lunasin market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lunasin Report?

Have a Query? Click Here

Other Related Reports

Vindesine Drugs Comprehensive Study by End-users (Academic & Research Institutes, Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies), Indications (Acute Leukaemia, Malignant Lympho...
$ 3650
Deuterated Drugs Comprehensive Study by Type (Austedo, Zepsun, Others), Disease (Huntington’s disease, Tardive Dyskinesia, Cancer, Others) Players and Region - Global Market Outlook to 2028
$ 3500
Carvedilol drug Comprehensive Study by Disease (Atrial Fibrillation, High Blood Pressure, Left ventricular dysfunction, Heart Failure, Angina, Others), Host (Injectable, Oral { Capsule, tablet, syrup...
$ 3450
Menopause Drugs Comprehensive Study by End-users (Hospitals & Clinics, Academia & Research), Symptoms (Hot flashes, Formication, Migraine, Fatigue, Anxiety, Irritability, Mood Swings, Others), Treatm...
$ 3350
Emphysema Drug- Comprehensive Study by Drugs (Aclidinium Bromide Oral Inhalation, Albuterol and Ipratropium, Alpha One-proteinase inhibitor, Indacaterol, Others), Therapy (Pulmonary Rehabilitation, N...
$ 3750
Tenosynovitis Drugs Comprehensive Study by Product type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antibiotics, Corticosteroids), End user (Hospitals, Drugstores, Others) Players and Region - Gl...
$ 3500